Risk Profile Improvements

  • Material Weakness (improved) — Disclosure controls upgraded from ineffective to effective, though underlying material weaknesses in financial systems and staffing persist.
NASDAQ: SCNX Scienture Holdings, Inc. 10-K

SCNX launches first FDA-approved product ARBLI, divests legacy units, removes going-concern doubt

Filed March 30, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 26, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SCNX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 4, 2026 12:52 AM